0000000000068924

AUTHOR

Catello Califano

showing 3 related works from this author

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical exper…

2020

No abstract available

Oncologymedicine.medical_specialtyElotuzumab lenalidomide dexamethasone salvage therapy multiple myelomaSalvage therapyAntibodies Monoclonal HumanizedAntibodiesDexamethasoneEfficacyInternal medicineMonoclonalAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalElotuzumabLetters to the EditorElotuzumab lenalidomide dexamethasone multiple myelomaHumanizedLenalidomideMultiple myelomaRetrospective StudiesLenalidomideSalvage Therapybusiness.industryRetrospective cohort studyHematologymedicine.diseaseClinical trialItalyAntibodies Monoclonal Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Italy; Lenalidomide; Retrospective Studies; Salvage Therapy; Multiple MyelomaMultiple Myelomabusinessmedicine.drug
researchProduct

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.

2018

© 2018 The Authors.

MaleCancer ResearchBoronic Acid[SDV]Life Sciences [q-bio]bortezomib ; global ; observational study ; routine practice ; stem cell transplantationSalvage therapyPractice PatternsDexamethasoneBortezomibRoutine practice0302 clinical medicineBortezomib; Global; Observational study; Routine practice; Stem cell transplantationhemic and lymphatic diseasesObservational studyAntineoplastic Combined Chemotherapy Protocols80 and overProspective StudiesPractice Patterns Physicians'Prospective cohort studyLenalidomideComputingMilieux_MISCELLANEOUSMultiple myelomaAged 80 and overBortezomibStem cell transplantationGlobalHematologyMiddle AgedBoronic Acids3. Good healthThalidomideSurvival RateTreatment OutcomeLocalOncology030220 oncology & carcinogenesisBortezomib; Global; Observational study; Routine practice; Stem cell transplantation; Hematology; Oncology; Cancer ResearchFemaleMultiple MyelomaBortezomib; Global; Observational study; Routine practice; Stem cell transplantation; Adult; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence Local; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome; Practice Patterns Physicians'; Salvage Therapymedicine.drugHumanAdultmedicine.medical_specialty/NOFollow-Up Studie03 medical and health sciencesInternal medicinemedicineHumansSurvival rateLenalidomideAgedSalvage TherapyPhysicians'Antineoplastic Combined Chemotherapy Protocolbusiness.industrySettore MED/15medicine.diseaseTransplantationThalidomideSettore MED/15 - MALATTIE DEL SANGUEProspective StudieNeoplasm RecurrenceNeoplasm Recurrence Localbusiness030215 immunologyFollow-Up StudiesClinical lymphoma, myelomaleukemia
researchProduct

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective cli…

2022

: The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyse…

Cancer Researchlenalidomidedexamethasone; elotuzumab; lenalidomide; multiple myeloma; salvage therapydexamethasoneHematologyGeneral MedicineAntibodies Monoclonal HumanizedelotuzumabThalidomidemultiple myelomaOncologyAntineoplastic Combined Chemotherapy ProtocolsHumanssalvage therapySettore MED/15 - Malattie del SangueFollow-Up StudiesRetrospective StudiesHematological Oncology
researchProduct